Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas

被引：11

作者：

Goldstein, David

El Maraghi, Robert Hassan

Hammel, Pascal

Heinemann, Volker

Kunzmann, Volker

Sastre, Javier

Scheithauer, Werner

Siena, Salvatore

Tabernero, Josep

Teixeira, Luis

Tortora, Giampaolo

Van Laethem, Jean-Luc

Young, Rosemary

Wei, Xinyu

Lu, Brian

Romano, Alfredo

Von Hoff, Daniel D.

机构：

[1] Prince Wales Hosp, Sydney, NSW, Australia

[2] Royal Victoria Reg Hlth Ctr, Barrie, ON, Canada

[3] Hop Beaujon, Clichy, France

[4] Univ Munich, Klinikum Grosshadern, Dept Med Oncol, D-80539 Munich, Germany

[5] Univ Wurzburg, Med Klin & Poliklin 2, D-97070 Wurzburg, Germany

[6] Hosp Clin San Carlos, Madrid, Spain

[7] Med Univ Wien, Vienna, Austria

[8] Azienda Osped Niguarda Ca Granda, Milan, Italy

[9] Vall dHebron Univ Hosp, Barcelona, Spain

[10] Hop St Antoine, F-75571 Paris, France

[11] Univ Verona, Azienda Osped Univ Integrata, I-37100 Verona, Italy

[12] Erasme Univ Hosp, B-1070 Brussels, Belgium

[13] Royal Hobart Hosp, Hobart, Tas, Australia

[14] Celgene Corp, Summit, NJ USA

[15] Celgene Int, Boudry, Switzerland

[16] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期

关键词：

D O I：

10.1200/jco.2014.32.3_suppl.178

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

178

引用

页数：1